Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tredaptive Safety Hazards Cast Shadow Over AbbVie’s Niaspan

Executive Summary

HPS2-THRIVE investigators say serious adverse bleeding and infection events are most likely due to the niacin component of Merck’s Tredaptive and advise caution using niacin in light of the risks. Abbvie’s Niaspan is the most likely branded casualty of the news, but the drug will be off-patent soon.

You may also be interested in...



New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials

The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.

Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class

Regeneron/Sanofi and Amgen stress the strengths of the Phase III PCSK9 development programs at the American College of Cardiology annual meeting. The mechanism of action holds appeal, but development is taking place at a time of skepticism about surrogate CV markers, following failed trials of other drugs.

HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers

While risks clearly outweigh benefits for niacin as an add-on therapy in the more than 25,000-patient HPS2-THRIVE study, investigators argue that the door is still open for other HDL-raising drugs. One panelist at the ACC meeting where results were presented calls for smaller, more targeted trials in the future.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel